Liraglutide Explained
Liraglutide is a synthetic peptide—basically a short chain of amino acids—that mimics a natural hormone your body already makes. It's prescribed for type 2 diabetes and weight management, and it's become popular because it actually helps your heart, not just your blood sugar or waistline.
Here's how it works: When you eat, your gut naturally releases a hormone called GLP-1 that tells your pancreas "hey, make some insulin." Liraglutide acts like a stand-in for that hormone, triggering the same response. It also tells your stomach to slow down digestion, so food moves through more gradually and you feel fuller longer—which is why people lose weight on it. Even more importantly, it reduces your appetite at a deeper level by signaling your brain's hunger center.
The clever part is that liraglutide doesn't just borrow the shape of GLP-1; it's nearly identical to it, and it's designed to stick around in your bloodstream for about 13 hours instead of minutes. That's why you only need one injection a week instead of several throughout the day.
Over time, liraglutide actually helps your pancreas preserve its ability to make insulin naturally. And research has shown it genuinely reduces heart attacks and strokes—a benefit that goes beyond just controlling blood sugar, suggesting it directly protects your heart tissue itself.
Dosage Information
Typical Dose
1.2-1.8 mg daily (diabetes), up to 3.0 mg daily (obesity)
Frequency
Once daily
Administration
Subcutaneous injection
Half-Life
13 hours
Notes
Titrated over 4-5 weeks. Requires medical supervision. Predecessor to semaglutide — semaglutide generally preferred for weight management due to once-weekly dosing and greater efficacy.
Why this matters
Shorter than semaglutide; requires once-daily injection for consistent effect.
Protocol cycle
Dose Calculator
Calculate your draw amount for an insulin syringe (U-100)
Draw to the
48
unit mark
Draw 48 units for your 1200mcg dose of Liraglutide
This calculator is for educational purposes. Always verify your calculations and consult a healthcare professional.
Where does Liraglutide sit?
See how this peptide compares across all 150 peptides in our database.
Evidence Score
0.69
Compound Data
Molecular Formula
C172H265N43O51
Molecular Weight
3751.00 g/mol
IUPAC Name
(2S)-5-[[(5S)-5-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]propanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-5-oxopentanoyl]amino]propanoyl]amino]propanoyl]amino]-6-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-carbamimidamido-1-[[2-[[(2S)-5-carbamimidamido-1-(carboxymethylamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-6-oxohexyl]amino]-2-(hexadecanoylamino)-5-oxopentanoic acid
PubChem CID
16134956Potential Side Effects
Liraglutide discussions
Quick Facts
- Administration
- Subcutaneous injection
- Typical Dose
- 1.2-1.8 mg daily (diabetes), up to 3.0 mg daily (obesity)
- Frequency
- Once daily
- References
- 0 curated + 36 from PubMed
- Clinical Trials
- 33 registered
- Evidence Score
- 0.7 / 100
Frequently Asked Questions about Liraglutide
What is Liraglutide?
Liraglutide is a GLP-1 receptor agonist approved by the FDA for type 2 diabetes (Victoza) and obesity management (Saxenda). It was the first GLP-1 analog to demonstrate cardiovascular risk reduction in a large outcomes trial (LEADER trial), establishing the cardiovascular benefits of this peptide class. Liraglutide has one of the most extensive clinical evidence bases of any metabolic peptide with over a decade of post-market safety data and multiple completed Phase 3 trials across diabetes, obesity, and cardiovascular disease.
How does Liraglutide work?
Liraglutide shares the core GLP-1 receptor agonist mechanism — stimulating insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite through central hypothalamic pathways. Its 97% homology to native GLP-1 and albumin-binding fatty acid chain give it a half-life of approximately 13 hours, enabling once-daily dosing. Liraglutide also has direct effects on pancreatic beta-cell proliferation and survival, potentially preserving insulin secretory capacity over time. Its cardiovascular benefits in the LEADER trial — reducing major adverse cardiovascular events by 13% — appear mediated through direct GLP-1 receptor effects on cardiomyocytes, endothelial cells, and inflammatory pathways.
What is the recommended dosage for Liraglutide?
The typical dose is 1.2-1.8 mg daily (diabetes), up to 3.0 mg daily (obesity). Once daily. Administration: Subcutaneous injection. Titrated over 4-5 weeks. Requires medical supervision. Predecessor to semaglutide — semaglutide generally preferred for weight management due to once-weekly dosing and greater efficacy.
What are the side effects of Liraglutide?
Nausea (very common). Vomiting (common). Diarrhea (common). Headache (common). Hypoglycemia when combined with insulin or sulfonylureas. Thyroid C-cell tumor risk (black box warning)
What is the Liraglutide cycle protocol?
Liraglutide is typically cycled continuous. Once daily dosing; initial titration phase 4-5 weeks
Questions reflect common community inquiries. This is not medical advice.